Skip to main content
. 2020 Feb 15;14(8):1066–1073. doi: 10.1093/ecco-jcc/jjaa027

Figure 3.

Figure 3.

CRP levels [observed median] in patients with CD and UC who completed Week 56 of the sub-study on Q8W dosing. Serum samples were obtained before vedolizumab dosing at enrolment in the sub-study [baseline] and at Weeks 8, 16, and 56. CD, Crohn’s disease; CRP, C-reactive protein; Q8W, every 8 weeks; UC, ulcerative colitis.